- News>
- Companies
Dolo-650 manufactures face Income Tax raids, searches conducted for alleged tax evasion
The IT department conducted raids at the premises of Bengaluru-based pharmaceutical company Micro Labs Ltd, the manufacturers of Dolo-650 tablet that was widely used by COVID-19 patients during the last over two years, on charges of alleged tax evasion.
Highlights
- Officials said the department is looking at financial documents, balance sheets and business distributor networks.
- The company said on its website that it was engaged in the making and marketing pharmaceutical products and APIs.
New Delhi: The Income Tax department Wednesday conducted searches at the premises of Bengaluru-based pharmaceutical company Micro Labs Ltd, the manufacturers of Dolo-650 tablet that was widely used by COVID-19 patients during the last over two years, on charges of alleged tax evasion. Officials said the department is looking at financial documents, balance sheets and business distributor networks of the company as part of the searches.
The PTI has sent queries on the action to the Dolo-650 manufacturing company and a response is awaited. (ALSO READ: Shares gain on finance, consumer boost after overnight oil selloff)
Some other linked locations of the company in other cities and those of its promoters and distributors are also being covered in the ongoing IT raids, they said. (ALSO READ: Google India launches Startup School, aims to guide 10,000 startups)
The company said on its website that it was engaged in the making and marketing pharmaceutical products and APIs (Active Pharmaceutical Ingredients) and has 17 manufacturing units across the country apart from conducting business overseas.
Its major pharma products are Dolo-650, Amlong, Lubrex, Diapride, Vildapride, Olmat, Avas, Tripride, Bactoclav, Tenepride-M and Arbitel.
Dolo-650, an analgesic (pain killer) and antipyretic (fever-reducing) was being prescribed by doctors and medical shop owners for coronavirus patients to reduce pain and fever, common symptoms caused by Covid.
In the words of the company, Dolo-650, is "virtually a household name across the country".
The company website showcased a news article, published in February, on its website that said: "The company has sold 350 crore tablets (of Dolo-650) since the Covid-19 outbreak in 2020, and earned revenues of Rs 400 crore in a year."
The CMD of the company, Dilip Surana, has been quoted in the story.